Literature DB >> 27619393

Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.

Nicholas Horton1, Xianrui Wu2, Jessica Philpott2, Ari Garber2, Jean-Paul Achkar2, Aaron Brzezinski2, Bret A Lashner2, Bo Shen3.   

Abstract

BACKGROUND: Inflammatory bowel diseases (IBDs) are considered immune-mediated disorders with dysregulated innate and adaptive immunities. Secondary immunogloblin deficiency can occur in IBD and its impact on the disease course of IBD is not clear. AIMS: We sought to determine associations between low IgG/G1 levels and poor clinical outcomes in IBD patients.
METHODS: This historic cohort study was performed on IBD patients with obtained IgG/IgG1 levels. The primary outcome was defined as any IBD-related bowel resection surgery and/or hospitalization. Subgroup analyses assessed particular surgical outcomes in Crohn's disease (CD), ulcerative colitis (UC) or indeterminate colitis (IC), and ileal pouch-anal anastomosis (IPAA). The secondary outcomes included IBD drug escalations and C. difficile or cytomegalovirus infections.
RESULTS: A total of 136 IBD patients had IgG/G1 levels checked and adequate follow-up, 58 (42.6 %) with normal IgG/G1 levels and 78 (57.4 %) having low levels. A total of 49 patients (62.8 %) with low immunoglobulin levels had IBD-related surgeries or hospitalizations, compared to 33 patients (56.9 %) with normal levels [odds ratio (OR) 1.28, 95 % confidence interval (CI) 0.64-2.56; p = 0.49]. Low IgG/G1 levels were associated with IBD-related surgery in CD in univariate analysis [hazard ratio (HR) 4.42, 95 % CI 1.02-19.23; p = 0.048] and in Kaplan-Meier survival curve analysis (p = 0.03), with a trend toward significance on multivariate analysis (HR 3.07, 95 % CI 0.67-14.31; p = 0.15). IBD patients with low IgG/G1 levels required more small bowel resections (12.8 vs. 1.7 %, p = 0.024) and 5-aminosalicylate initiations (28.2 vs. 13.8 %, p = 0.045).
CONCLUSIONS: Our study demonstrated a possible association between low IgG/G1 levels and poor outcomes in CD including surgery. Future implications include using immunoglobulin levels in IBD patients as a prognostic indicator or boosting humoral immunity as a treatment in this subset.

Entities:  

Keywords:  Clinical outcomes; Crohn’s disease; Immunoglobulins; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27619393     DOI: 10.1007/s10620-016-4294-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Disease activity and serum proteins in ulcerative colitis. Immunochemical quantitation.

Authors:  I L Marner; S Friborg; E Simonsen
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

Review 2.  Intravenous immunoglobulin for the treatment of Crohn's disease.

Authors:  Moshe Rogosnitzky; Rachel Danks; Daniel Holt
Journal:  Autoimmun Rev       Date:  2012-05-08       Impact factor: 9.754

3.  Serum immunoglobulin levels in ulcerative colitis: an investigation.

Authors:  C A Armstrong-Esther; A Williams
Journal:  Nurs Times       Date:  1976-09-23

4.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

5.  Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.

Authors:  Stefan Schreiber; Jean-Frédéric Colombel; Ralph Bloomfield; Susanna Nikolaus; Jürgen Schölmerich; Julian Panés; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2010-03-16       Impact factor: 10.864

6.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

7.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

8.  Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.

Authors:  A Chrissafidou; M Malek; E Musch
Journal:  Z Gastroenterol       Date:  2007-07       Impact factor: 2.000

Review 9.  Innate and adaptive immunity in inflammatory bowel diseases.

Authors:  Sebastian Foersch; Maximilian J Waldner; Markus F Neurath
Journal:  Dig Dis       Date:  2013-11-14       Impact factor: 2.404

10.  Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease.

Authors:  Tarun Rai; Xianrui Wu; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-01-30
View more
  4 in total

1.  IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4.

Authors:  Xiaowei Chen; Wenwen Sun; Risheng Lin; Zhiming Huang; Weichang Chen
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

2.  Adaptive Returns of Deficient Systemic Plasma Immunoglobulin G Levels as Rehabilitation Biomarker After Emergency Colectomy for Fulminant Ulcerative Colitis.

Authors:  Alexander T Hawkins; Jun W Um; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2017-12-13

3.  Anti-Inflammatory, Antioxidant, and Microbiota-Modulating Effects of Camellia Oil from Camellia brevistyla on Acetic Acid-Induced Colitis in Rats.

Authors:  Chun-Ching Wu; Yu-Tang Tung; Sheng-Yi Chen; Wei-Ting Lee; Hsin-Tang Lin; Gow-Chin Yen
Journal:  Antioxidants (Basel)       Date:  2020-01-08

Review 4.  Secondary causes of inflammatory bowel diseases.

Authors:  Yezaz A Ghouri; Veysel Tahan; Bo Shen
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.